TFB1M

Across TCGA pan-cancer cohorts, TFB1M mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of TFB1M’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where TFB1M mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types TFB1M is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.

CCRCC, COAD, and LSCC are the cancer types where TFB1M tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TFB1M mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	−0.741	<.001	11	view →
COAD	Male	III,IV	+0.555	<.001	9	view →
LSCC	Male	III,IV	+0.652	<.001	8	view →
LUAD	Female	All	+0.329	<.001	8	view →
HNSC	All	All	+0.165	.004	8	view →
OV	All	All	+0.372	.007	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

TFB1M–CCRCC

Open the CCRCC breakdown →